Bharat Book Bureau

The global clinical trials business worth is estimated $50 Billion in 2008, with a growth rate of 10%.The market will show considerable growth in the future. An increased emphasis has been placed on cost-effectiveness of pharmaceutical R&D, as well as increased productivity to maintain the high output of recent years. Consequently, the pharmaceutical industry has witnessed rapid expansion of outsourced clinical services in both the West and in developing nations, most notably India and China. Importantly, pharmaceutical and biotechnological companies are increasingly delegating the responsibility of clinical trials to contract research organisations (CROs).The majority of the revenues generated by the clinical trials industry are due to large pharmaceutical companies outsourcing clinical research, the most crucial and expensive stage of drug development, to companies specialising in that work. The major challenge for the pharmaceutical companies in the next five years will be to maintain high growth rates. The branded pharmaceuticals market is under substantial pressure due to: Existing generic competition, Impending loss of major patents, and relatively thin pipeline.Because of the nature of the clinical trials industry it will, in turn, experience increasing pressures to deliver a cost-effective service. The demand among drugs companies for a more cost-efficient pipeline has therefore intensified in recent years. The strategy that pharmaceutical companies now seem to be applying to clinical trials mirrors the latest trends in the drug discovery section of development.Contract research organisations (CROs) are playing increasingly vital roles on behalf of manufacturers in the global drug development process, from conducting Phase I trials to post-marketing studies. It is often difficult for pharmaceutical and biotech companies to decide which CRO to offer a contract to. However, the market is undergoing rapid change over the coming years, with different companies approaching the challenges in different ways. The CRO market, however, continues to grow steadily at an average 10% yearly growth rate.Bharatbook.com included a new report “Global Clinical Trial Business Report & Analysis 2008-2018” which investigates the global market for such services, providing forecasts for revenues and expenditure there, as well as a comprehensive examination of principles driving and restraining the clinical trials market worldwide.  In Global Clinical Trial Business 2008-2018 provides the following essential information for understanding the clinical trial business:• The value of the clinical trial business market and its principal market segments from 2008 to 2018
• Which current or future therapies that will drive the market for clinical trial business from 2008 to 2018
• Market drivers and restraints, including a comprehensive SWOT analysis
• Comprehensive views of key opinion leaders on clinical trial business
• The companies involved in clinical trial business and their business strategy
• Forecasts for revenue in each of the phases of clinical trial business
• The present state of clinical trial business and future trends there
• What contract research opportunities exist for market entrants, both established companies and newcomers
• The main concerns for outsourcing clinical trials to CROs
• Ways to improve cost-effectiveness of clinical trial business
• Changes in clinical trial regulations
• Focus on drug safety issues.About Bharatbook.com:Bharat Book Bureau facilitates companies to take the lead of their industry with best practice business strategies and intelligence, through a unique combination of published reports, databases, country reports, company profiles and customized research services. Bharat Book Bureau provides strategic information tools to the executives, business analysts, and knowledge managers that will help them to probe into and support critical, timely business decisions and strategies.For further information kindly visit: http://www.bharatbook.com/detail.asp?id=81654